An ongoing tribute. An important cause.

The Leland McSpadden
Memorial Research Fund

 

Meaningful Treatment for Lowe syndrome by 2030.

The LSA has an aggressive goal to make accessible a meaningful treatment for Lowe syndrome by 2030. Our international collaboration brings together researchers, clinicians families and those with lived experience. We strive to:
 
Icon for Advance our understanding of the metabolic basis of LS, especially how a phosphatidylinositol enzyme deficiency leads to the various features of LS
Advance our understanding of the metabolic basis of LS, especially how a phosphatidylinositol enzyme deficiency leads to the various features of LS
Icon for Develop a better understanding and treatment of the major complications of LS including but not limited to neurologic and behavioral problems, corneal keloid, degenerative bone and joint disorders, and renal diseases.
Develop a better understanding and treatment of the major complications of LS including but not limited to neurologic and behavioral problems, corneal keloid, degenerative bone and joint disorders, and renal diseases.
Icon for Foster Global Collaboration- LSA-funded research has led to the development of animal models used by researchers for kidney and brain research.
Foster Global Collaboration- LSA-funded research has led to the development of animal models used by researchers for kidney and brain research.
Icon for Support Testing of FDA Approved/Repurposed Drugs: Testing the safety profile, increasing sample sizes, and ultimately moving to clinical trials.
Support Testing of FDA Approved/Repurposed Drugs: Testing the safety profile, increasing sample sizes, and ultimately moving to clinical trials.
Icon for Drive Improvement of a Global Patient Registry: This registry houses the critical data we need to drive research and to understand the nuances between individuals with Lowe syndrome.
Drive Improvement of a Global Patient Registry: This registry houses the critical data we need to drive research and to understand the nuances between individuals with Lowe syndrome.
Icon for Enable LS individuals, Families, Clinical, and Research Experts to Connect: We host international conferences providing a platform for sharing knowledge and fostering collaboration.
Enable LS individuals, Families, Clinical, and Research Experts to Connect: We host international conferences providing a platform for sharing knowledge and fostering collaboration.
About Background




Grant History

2023

SKIP TO YEAR
Group 3
Oval
 
2023

Group 5

Dr. Francesco Emma, MD, Head of the Pediatric Nephrology & Department of Pediatric Subspecialties. Bambino Gesù Children’s Hospital, Italy

2023

Group 5

Leopoldo Staino, PhD Telethon Institute of Genetics and Medicine (TIGEM)

2023

Group 5

Dr. Jennifer L. Gallop, Department of Biochemistry University of Cambridge

2021

Group 5

R. Claudio Aguilar, Associate Professor, Assistant Head and Showalter Faculty Scholar, Department of Biological Sciences, Purdue University in West Lafayette, IN

2020

Group 5

Herb Lachman, M.D., Professor, Departments of Psychiatry, Medicine, Neuroscience, Genetics, Albert Einstein College of Medicine.

2019

Group 5

R. Claudio Aguilar, Associate Professor, Assistant Head and Showalter Faculty Scholar, Department of Biological Sciences, Purdue University in West Lafayette, IN

2018

Group 5

Herb Lachman, M.D., Professor, Departments of Psychiatry, Medicine, Neuroscience, Genetics, Albert Einstein College of Medicine.

2018

Group 5

R. Claudio Aguilar, Associate Professor, Assistant Head and Showalter Faculty Scholar, Department of Biological Sciences, Purdue University in West Lafayette, IN

2016

Group 5

Herb Lachman, M.D., Professor, Departments of Psychiatry, Medicine, Neuroscience, Genetics, Albert Einstein College of Medicine.

2015

Group 5

Robert L. Nussbaum, M.D. Chief, Division of Medical Genetics, Department of Medicine and the Institute for Human Genetics, University of California, San Francisco Box 0794, 513 Parnassus Ave, San Francisco, CA.

2014

Group 5

Ora A. Weisz, Ph.D., Associate Professor, Departments of Medicine (Renal-Electrolyte Division) and Cell Biology and Physiology, University of Pittsburgh School of Medicine in Pittsburg, PA.

2013

Group 5

Antonella De Matteis, MD, Programme Director of Cell Biology of Genetic Diseases, Telethon Institute of Genetics and Medicine (TIGEM) Via Pietro Castellino, 111 Napoli, 80131 Italy

2013

Group 5

Yang (“Young”) Sun, M.D., Ph.D. , Assistant Professor of Ophthalmology, Biochemistry and Molecular Biology in Eugene Marilyn Glick Eye Institute of Indiana University School of Medicine, Indianapolis, IN

2013

Group 5

Ora A. Weisz, Ph.D., Associate Professor, Departments of Medicine (Renal-Electrolyte Division) and Cell Biology and Physiology, University of Pittsburgh School of Medicine in Pittsburg, PA

2013

Group 5

Robert L. Nussbaum, M.D., Chief, Division of Medical Genetics, Department of Medicine and the Institute for Human Genetics, University of California, San Francisco Box 0794, 513 Parnassus Ave, San Francisco, CA

2013

Group 5

Antonella De Matteis, MD, Programme Director of Cell Biology of Genetic Diseases, Telethon Institute of Genetics and Medicine (TIGEM) Via Pietro Castellino, 111 Napoli, 80131 Italy

2012

Group 5

Avital Rodal, Ph.D., Associate Professor, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, MA

2011

Group 5

Laura E. Swan, Ph.D., Department of Cell Biology, Yale University School of Medical in New Haven, CT.

2010

Group 5

Avital Rodal, Ph.D., Associate Professor, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, MA

2009

Group 5

Zelig S. Dolinsky, Ph. D. Biomedical Research Consultant, Manchester, CT

2008

Group 5

Ora A. Weisz, Ph.D., Associate Professor, Departments of Medicine (Renal-Electrolyte Division) and Cell Biology and Physiology, University of Pittsburgh School of Medicine in Pittsburg, PA

2008

Group 5

Pietro De Camilli, M.D., Department. of Cell Biology and HHMI, Yale University School of Medical in New Haven, CT.

2008

Group 5

Zelig S. Dolinsky, Ph. D. Biomedical Research Consultant, Manchester, CT

2007

Group 5

Yuxin Mao, Ph.D., Department. of Cell Biology and HHMI, Yale University School of Medical in New Haven, CT.

2007

Group 5

Ora A. Weisz, Ph.D., Associate Professor, Departments of Medicine (Renal-Electrolyte Division) and Cell Biology and Physiology, University of Pittsburgh School of Medicine in Pittsburg, PA.

2005

Group 5

Maria Antonietta DeMatteis, M.D., Head of the Laboratory of Physiopathology of Secretion within the Department of Cell Biology and Oncology in Consorzio Mario Negri Sud, Chieti, Italy

2003

Group 5

Erik M. Jorgensen, Ph.D., and Kimberly R. Schuske, Ph.D., Department of Biology, University of Utah.

2002

Group 5

Erik M. Jorgensen, Ph.D., and Kimberly R. Schuske, Ph.D., Department of Biology, University of Utah.

2002

Group 5

Jeremy W. Thorner, Ph.D., Department of Molecular and Cell Biology, University of California/Berkeley.

2000

Group 5

Bonnie Blazer-Yost, Ph.D., Biology Department, Indiana University/Purdue University in Indianapolis, IN.

1999

Group 5

Dewey Royal, Ph.D., Department of Molecular Biology and Biochemistry at Rutgers University.

1999

Group 5

Ti Lin, Ph.D., formerly of the Georgetown University Medical Center, currently at the National Institutes of Health in collaboration with Johns Hopkins Bayview Medical Center.

1999

Group 5

Bonnie Blazer-Yost, Ph.D., Biology Department, Indiana University/Purdue University in Indianapolis, IN.

1996

Group 5

Richard A. Lewis, M.D., Baylor College of Medicine.

1993

Group 5

Lawrence Charnas, M.D., Ph.D., St. Mary’s Hospital Cancer Research Institute.

1993

Group 5

Lorraine C. Racusen, M.D., Johns Hopkins University School of Medicine.

1989

Group 5

Richard A. Lewis, M.D., Baylor College of Medicine.

1988

Group 5

Richard A. Lewis, M.D., Baylor College of Medicine.